Xenon Pharmaceuticals at Goldman Sachs Conference

 On Tuesday, 10 June 2025, Xenon Pharmaceuticals (NASDAQ:XENE) presented at the Goldman Sachs 46th Annual Global Healthcare Conference 2025. The company outlined its strategic focus on advancing clinical programs for its lead molecule, Zeto counter, in epilepsy and major depressive disorder (MDD). While the company is optimistic about its clinical and commercial prospects, challenges remain in executing its ambitious plans.

Key Takeaways

• Xenon is advancing its lead molecule, Zeto counter, with a focus on epilepsy and MDD.
• The company expects Phase III data for Zetucalder in focal onset seizures by early 2026.
• Xenon plans to build a commercial infrastructure in the US, seeking partners for ex-US markets.
• A strong cash position extends the company’s financial runway into 2027.
• Xenon is exploring the potential of Zeto counter in bipolar depression.

Financial Results

• Cash Position and Runway:

- Xenon ended Q1 with just under $700 million.

- The company projects a cash runway extending into 2027, covering all planned clinical trials and drug discovery efforts.

• Commercialization Strategy:

- Plans to establish a US commercial infrastructure for AZET2 Calynur.

- Seeking partnerships for market access outside the US.

Operational Updates

• Zeto Counter (Epilepsy):

- EXTOL-2 (Phase III in focal onset seizures) nearing completion, with data expected in early 2026.

- XTOL-3 enrolling at various centers, similar criteria as XTOL-2.

- EXACT (Phase III in Primary Generalized Tonoclonic Seizures) facing longer enrollment due to patient scarcity.

• Zeto Counter (MDD):

- ExNova 2 (Phase III) active in approximately 50 US centers, with guidance expected soon.

- ExNova 3 to start at different centers, including some outside the US.

• Zeto Counter (Bipolar Depression):

- Phase III program set to begin mid-year.

Future Outlook

• Clinical Data Readouts:

- Significant milestones expected during the cash runway, with epilepsy data anticipated in early 2026.

• Pipeline Development:

- Focus on advancing KV7 molecules, Nav1.7 inhibitors, and Nav1.1 potentiators.

• Market Expansion:

- Exploring partnerships for ex-US markets.

• Commercial Launch:

- Aiming for AZET2 Calynur commercialization by late 2026 or 2027.

Q&A Highlights

• Commercial Strategy:

- Xenon to build US infrastructure and seek ex-US partners.

- Investment in MSLs to enhance presence in the epilepsy community.

• Pricing:

- Epilepsy drugs typically priced in the specialty neurology range.

- Similar pricing expected for branded drugs in epilepsy and depression.

• Competition:

- Xenon anticipates being one of two branded drugs available, alongside XCOPRI.

For more detailed insights, readers are encouraged to refer to the full conference call transcript.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference 2025:

https://www.investing.com/news/transcripts/xenon-pharmaceuticals-at-goldman-sachs-conference-strategic-clinical-advances-93CH-4089927

TG Therapeutics at Goldman Sachs Conference

 On Tuesday, 10 June 2025, TG Therapeutics (NASDAQ:TGTX) presented at the Goldman Sachs 46th Annual Global Healthcare Conference 2025. The company discussed its strategic initiatives and future growth plans, focusing on Breumvy, its commercial-stage drug for B cell diseases. While TG Therapeutics highlighted positive developments in market share and innovation, challenges remain in expanding their pipeline and maintaining competitive positioning.

Key Takeaways

• TG Therapeutics is committed to growing its market share in the CD20 therapy space, focusing on Breumvy’s performance and patient experience.
• The company is investing in marketing and development, aiming to enhance Breumvy’s dosing and formulation.
• A share buyback program is underway, reflecting confidence in long-term growth.
• Future expansion includes potential new indications and partnerships, particularly in neurological conditions.
• Financial guidance for Breumvy’s full-year revenue is set at $560 million.

Financial Results

• TG Therapeutics provided a revenue guidance of $560 million for Breumvy in 2025.
• The company’s revenue drivers include new patient starts and persistence in treatment.
• A share buyback program has been initiated, indicating a focus on shareholder value.

Operational Updates

• The company has achieved parity in formulary coverage with competitors such as Ocrevus, with some plans preferring Breumvy.
• TG Therapeutics has doubled its field force since the drug’s launch, leading to increased market penetration.
• Marketing efforts have expanded to include online platforms, testimonials, and connected TV commercials.
• The company is working on consolidating Breumvy’s dosing to a single day and developing a 30-minute infusion option.
• A subcutaneous formulation is in development to compete with at-home injection options like Kesimpta.
• 
  
• Future Outlook

• TG Therapeutics is exploring new indications for Breumvy, including MG, and is investing in a CAR T program.
• The company is targeting neurological conditions such as NMO and CIDP for future pipeline expansion.
• A subcutaneous formulation with potential for Q2 month or Q3 month dosing regimens is being developed.

Q&A Highlights

• An unidentified speaker emphasized the importance of realistic performance estimates and the company’s goal to lead in dynamic market share for CD20 therapies.
• The company remains open to new product opportunities and partnerships that align with its strategic goals.

For more detailed insights, readers are encouraged to refer to the full transcript below.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference 2025:

https://www.investing.com/news/transcripts/tg-therapeutics-at-goldman-sachs-conference-strategic-growth-and-innovations-93CH-4089494

Amgen at Goldman Sachs Healthcare

 On Tuesday, 10 June 2025, Amgen Inc. (NASDAQ:AMGN) presented at the Goldman Sachs 46th Annual Global Healthcare Conference 2025, highlighting its robust first-quarter performance and strategic initiatives. The company reported a 9% revenue increase and a 24% rise in non-GAAP EPS year-over-year, driven by strong product performance and innovation. While the company is investing heavily in pipeline expansion and manufacturing capacity, it remains focused on returning to pre-acquisition debt levels by year-end.

Key Takeaways

• Amgen’s Q1 2025 revenue grew by 9%, with non-GAAP EPS up 24% year-over-year.
• Key products like Repatha, Evenity, and TESPIRE showed significant growth.
• The company is focusing on expanding manufacturing capacity and pipeline advancements.
• Amgen aims to address the obesity market with its weight management drug, Meritide.
• The company is committed to strategic collaborations and returning to pre-acquisition debt levels.

Financial Results

Amgen reported a strong financial performance in the first quarter of 2025:

• Revenue increased by 9% year-over-year.
• Non-GAAP EPS rose by 24% compared to the previous year.
• Biosimilars product sales reached $735 million, marking a 35% increase.
• Operating margin is expected to be around 46% for the year, slightly down from 47% due to pipeline investments.

Operational Updates

The company is making significant strides in its operations:

• Meritide’s Phase III studies are underway, with data to be presented at the ADA meeting.
• Euplisna was launched as an FDA-approved therapy for IgG4-related disease.
• TESPIRE is advancing in additional indications, with important PDUFA dates approaching.
• New investments include over $1 billion in North Carolina and $900 million in Ohio for manufacturing facilities.
• 
  
• Future Outlook

Amgen’s strategic focus includes:

• Continuing to execute its end-market portfolio and pipeline strategies.
• Anticipating significant readouts from ongoing clinical trials, including bema rituximab and Repatha Vesalius.
• Preparing for potential impacts from tariffs, taxes, and pricing changes.
• Ensuring capital allocation supports innovation and market readiness.

Q&A Highlights

Key discussions from the Q&A session included:

• Detailed insights into Meritide’s potential and upcoming data presentations.
• Expectations for the Opasiran secondary prevention study readout next year.
• Recent APLIZMA approval and its implications for IgG4-mediated diseases.
• The promising outlook for Amgen’s T cell engager platform in improving cancer survival rates.

For a detailed understanding of Amgen’s strategic initiatives and financial performance, refer to the full transcript below.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference 2025:

https://www.investing.com/news/transcripts/amgen-at-goldman-sachs-healthcare-strategic-growth-and-innovation-93CH-4089286